Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc; Liraglutide

Criteria

Inclusion Criteria:

• Diagnosed with type 2 diabetes

• BMI less than 45.0 kg/m2

• Insulin naive

• Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%

Exclusion Criteria:

• Any clinically significant disease other than type 2 diabetes

• Currently using daily insulin

• Thiazolidinione use or other injectable diabetes medications within the last 3 months